Global Capabilities
Headquartered in Cheshire, Connecticut, Alexion employs more than 500 people around
the world. In addition to our corporate headquarters, Alexion’s facilities include
a manufacturing plant in Smithfield, Rhode Island, EMEA (Europe, Middle East &
Africa) regional headquarters in Lausanne, Switzerland, a European shared service
center in Paris, distribution and sales operations in major markets throughout Europe,
and new operations in Sydney, Australia, Sao Paulo, Brazil, Ontario, Canada and
Tokyo, Japan. The company is also expanding its reach in Latin America, the Middle
East and Africa.
Alexion’s global presence reflects the approval of Soliris for the treatment of
patients with PNH in the United States, 29 European countries, Australia and Canada.
The company has also submitted a marketing application in Japan, and is working
toward seeking regulatory approval in other countries of Asia and South America.